तुलना करने के लिए मीट्रिक्स | GLMD | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGLMDपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.3x | −1.5x | −0.4x | |
PEG अनुपात | 0.00 | 0.00 | 0.00 | |
क़ीमत/बुक | 0.2x | 1.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 6.5x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 440.1% | 47.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 24.3% | 6.3% | अनलॉक करें |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.